Oncology

Tissue factor (TF) ) is expressed at very high levels on tumors and their blood vessels (vasculature) in a broad range of solid tumors. We have developed an anti-body drug conjugate (ADC) targeted to TF which is now partnered with Exelixis. Exelixis announced the initiation of Phase I clinical trials in 2021. More information is available on the company’s website (www.exelixis.com).